We are live on ! Find out more

UPB

Upstream Bio Inc

UPB

Market cap $257M

4.70 USD

+0.15

3.3%

At close Updated Oct 9, 4:00 PM EDT

Pre-market

After hours

4.70

0.00

0%

1 day

3.3%

5 days

-7.3%

1 month

-21.14%

3 months

-39.82%

6 months

-54.89%

Year to date

-82.64%

1 year

-76.25%

5 years

-78.64%

10 years

-78.64%

About: Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases. Verekitug has advanced into three separate world-wide, placebo-controlled, randomized Phase 2 clinical trials, two completed in chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma, and one ongoing in chronic obstructive pulmonary disease (COPD).

Employees: 75

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 40%

Neutral 40%

Negative 20%

These beaten-down stocks could bounce back in January, if history is any guide

Tax-loss selling is likely to lead these 20 stocks to become artificially depressed in the fourth quarter — and therefore good bets to bounce back in the new year

These beaten-down stocks could bounce back in January, if history is any guide

Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026

– Verekitug, 100 mg dosed every 12 weeks, reduced AAER by 56% compared to placebo in patients with severe asthma – – Verekitug also delivered clinically meaningful improvements in lung function (FEV 1 ) and exhaled nitric oxide (FeNO) with every 12-week dosing – – The Company remains on track to initiate Phase 3 trials in severe asthma and CRSwNP in Q1 2027 , designed to deliver best-in-class efficacy in both indications by evaluating a 400 mg quarterly regimen of verekitug in broad patient populations – WALTHAM, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for severe inflammatory respiratory diseases, today presented results from the Phase 2 VALIANT clinical trial evaluating the safety and efficacy of verekitug in adults with severe asthma in a late-breaking oral presentation at the European Respiratory Society (ERS) Congress 2026 in Barcelona.

Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026

Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP

– Following productive FDA discussions, Upstream Bio will study 400 mg of verekitug administered every 12 weeks, versus placebo, in severe asthma and CRSwNP with one pivotal Phase 3 trial in each indication – – The Company's Phase 3 strategy is designed to deliver best-in-class efficacy across both indications by evaluating a high-dose, quarterly regimen of verekitug in broad patient populations – – The Company remains on track to initiate both Phase 3 trials in Q1 2027 – WALTHAM, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for severe inflammatory respiratory diseases, today announced its pivotal Phase 3 development plans for verekitug in severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP).

Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP

Zacks Investment Research

Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates

Upstream Bio, Inc. (UPB) came out with a quarterly loss of $0.73 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to a loss of $0.74 per share a year ago.

Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates

Zacks Investment Research

Upstream Bio, Inc. (UPB) Upgraded to Buy: What Does It Mean for the Stock?

Upstream Bio, Inc. (UPB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Upstream Bio, Inc. (UPB) Upgraded to Buy: What Does It Mean for the Stock?

Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026

– Verekitug, administered once every three months, led to clinically meaningful improvements in nasal polyp score (NPS) in approximately 80% of participants –

Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026

KBRA Assigns Preliminary Ratings to OBX 2026-AHC2 Trust

NEW YORK--(BUSINESS WIRE)-- #creditratingagency--KBRA assigns preliminary ratings to 65 classes of mortgage pass-through notes from OBX 2026-AHC2 Trust, a prime agency-eligible RMBS transaction sponsored by Onslow Bay Financial LLC, that is fully originated and serviced by AmeriHome Mortgage Company, LLC (AmeriHome). This transaction is comprised of 599 residential mortgages with an aggregate unpaid principal balance (UPB) of approximately $340.0 million as of the June 1, 2026 cut-off date. The underlying collateral.

KBRA Assigns Preliminary Ratings to OBX 2026-AHC2 Trust

Upstream Bio, Inc. (UPB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Upstream Bio, Inc. (UPB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Upstream Bio, Inc. (UPB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026

WALTHAM, Mass., June 08, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that additional data from its Phase 2 VIBRANT trial of verekitug in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) will be presented in an oral session at the European Academy of Allergy and Clinical Immunology (EAACI) 2026 Congress in Istanbul, Turkey, on Sunday, June 14, 2026.

Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026

Upstream Bio to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

WALTHAM, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream Bio, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Wednesday, June 10, 2026, at 10:40 a.m.

Upstream Bio to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

See News Rankings

Price charts implemented using Lightweight Charts™